Nathan J. Dowden Sells 1,018 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDAGet Rating) COO Nathan J. Dowden sold 1,018 shares of Entrada Therapeutics stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $15.07, for a total transaction of $15,341.26. Following the completion of the transaction, the chief operating officer now directly owns 64,355 shares in the company, valued at $969,829.85. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Entrada Therapeutics Stock Performance

TRDA traded up $1.66 during trading on Friday, hitting $15.09. The stock had a trading volume of 38,563 shares, compared to its average volume of 91,097. The firm has a market capitalization of $473.34 million and a P/E ratio of -1.25. The company’s 50-day moving average price is $12.63 and its 200 day moving average price is $9.90. Entrada Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $36.85.

Entrada Therapeutics (NASDAQ:TRDAGet Rating) last issued its earnings results on Thursday, August 11th. The company reported ($0.74) EPS for the quarter.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors have recently made changes to their positions in TRDA. New York State Common Retirement Fund purchased a new stake in shares of Entrada Therapeutics during the 1st quarter worth $46,000. Bank of New York Mellon Corp boosted its position in shares of Entrada Therapeutics by 60.6% in the 1st quarter. Bank of New York Mellon Corp now owns 21,933 shares of the company’s stock worth $206,000 after buying an additional 8,276 shares in the last quarter. Ghisallo Capital Management LLC purchased a new stake in shares of Entrada Therapeutics in the 4th quarter worth about $257,000. Walleye Capital LLC purchased a new stake in shares of Entrada Therapeutics in the 1st quarter worth about $419,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Entrada Therapeutics by 7.3% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,704 shares of the company’s stock worth $646,000 after buying an additional 4,685 shares in the last quarter. 79.02% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group boosted their price objective on shares of Entrada Therapeutics from $10.00 to $13.00 and gave the company a “neutral” rating in a research note on Tuesday, August 16th.

Entrada Therapeutics Company Profile

(Get Rating)

Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.

Featured Stories

Insider Buying and Selling by Quarter for Entrada Therapeutics (NASDAQ:TRDA)

Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.